P2X7 receptor antagonists modulate experimental autoimmune neuritis via regulation of NLRP3 inflammasome activation and Th17 and Th1 cell differentiation

Yuhan Xie,Ranran Han,Yulin Li,Weiya Li,Shichao Zhang,Yu Wu,Yuexin Zhao,Rongrong Liu,Jie Wu,Wei Jiang,Xiuju Chen

DOI: https://doi.org/10.1186/s12974-024-03057-z

IF: 9.3

2024-03-27

Journal of Neuroinflammation

Abstract:Guillain–Barré syndrome (GBS), a post-infectious, immune-mediated, acute demyelinating disease of the peripheral nerves and nerve roots, represents the most prevalent and severe acute paralyzing neuropathy. Purinergic P2X7 receptors (P2X7R) play a crucial role in central nervous system inflammation. However, little is known about their role in the immune-inflammatory response within the peripheral nervous system.

immunology,neurosciences

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to explore the role of purinergic receptor P2X7 (P2X7R) in Guillain - Barré syndrome (GBS) and its potential as a therapeutic target. Specifically, through the experimental autoimmune neuritis (EAN) model, the study explored the role of P2X7R in neuroinflammation, especially its regulatory role in CD4+ T - cell differentiation and NLRP3 inflammasome activation. The study aimed to verify whether inhibiting P2X7R can alleviate the symptoms of EAN, improve nerve conduction function, and reduce the inflammatory response. ### Main research questions: 1. **Expression of P2X7R in GBS patients and EAN model**: The study first evaluated the expression level of P2X7R in the peripheral blood of GBS patients and further explored the expression changes of P2X7R in CD4+ T - cells, CD8+ T - cells and macrophages through the EAN model. 2. **Effect of P2X7R antagonist BBG on EAN symptoms**: By using the P2X7R antagonist BBG, the researchers investigated the alleviating effect of BBG on neurological symptoms in the EAN model, including improvements in nerve function scores, inflammatory cell infiltration, degree of demyelination, and nerve conduction velocity. 3. **Role of P2X7R in CD4+ T - cell differentiation and NLRP3 inflammasome activation**: The study analyzed the role of P2X7R in CD4+ T - cell differentiation, especially its influence on Th1 and Th17 cell differentiation, through methods such as flow cytometry and immunofluorescence staining. Meanwhile, the study also explored how P2X7R inhibition affects the activation of NLRP3 inflammasome and the expression of its downstream signaling molecules. 4. **Effect of P2X7R inhibition on the expression of inflammatory factors**: The study detected the changes in mRNA and protein levels of inflammatory factors (such as IL - 17, IFN - γ, TNF - α and IL - 2) in the EAN model after P2X7R inhibition by qRT - PCR and Western Blot techniques. ### Research conclusions: The study found that P2X7R was up - regulated in both GBS patients and the EAN model, especially in CD4+ T - cells. Inhibiting P2X7R can significantly alleviate the symptoms of EAN, improve nerve conduction function, reduce inflammatory cell infiltration and demyelination, and simultaneously inhibit the differentiation of Th1 and Th17 cells, and reduce the activation of NLRP3 inflammasome and the expression of its downstream inflammatory factors. These results suggest that P2X7R may be a potential target for GBS treatment.

P2X7 receptor antagonists modulate experimental autoimmune neuritis via regulation of NLRP3 inflammasome activation and Th17 and Th1 cell differentiation

Lactobacillus Rhamnosus Ameliorates Experimental Autoimmune Neuritis Via Modulation of Gut Microbiota and Metabolites.

M1 Macrophage Derived Exosomes Aggravate Experimental Autoimmune Neuritis via Modulating Th1 Response

Critical Role of P2Y 12 Receptor in Regulation of Th17 Differentiation and Experimental Autoimmune Encephalomyelitis Pathogenesis.

P2X7 Receptor of Microglia Mediates Neuropathic pain by Regulating Autophagy After Chronic-Constriction Injury

Tumor Necrosis Factor-Α in Guillain-Barré Syndrome, Friend or Foe?

P2Y12 Receptor Mediates Apoptosis and Demyelination to Affect Functional Recovery in Mice with Spinal Cord Injury.

Autoreactive T cells target peripheral nerves in Guillain–Barré syndrome

Nerve modulation therapy in gouty arthritis: targeting increased sFRP2 expression in dorsal root ganglion regulates macrophage polarization and alleviates endothelial damage

Involvement of Microglial P2X7 Receptors and Downstream Signaling Pathways in Long-Term Potentiation of Spinal Nociceptive Responses

P2X7 receptor: A potential therapeutic target for autoimmune diseases

A pathologically expanded, clonal lineage of IL-21 producing CD4+ T cells drives Inflammatory neuropathy

GPR34 senses demyelination to promote neuroinflammation and pathologies

P2 Receptors for Extracellular Nucleotides in the Central Nervous System: Role of P2X7 and P2Y2 Receptor Interactions in Neuroinflammation

P2R Inhibitors Prevent Antibody-Mediated Complement Activation in an Animal Model of Neuromyelitis Optica : P2R Inhibitors Prevent Autoantibody Injury

Guillain-Barré syndrome: immunopathogenesis and therapeutic targets

P2X7R in periaqueductal gray matter participates in nociception modulation of chronic neuropathic pain

Causal effects of systemic inflammatory proteins on Guillain-Barre Syndrome: insights from genome-wide Mendelian randomization, single-cell RNA sequencing analysis, and network pharmacology

P2X7-related modulation of pathological nociception in rats

Anti-inflammatory Mechanisms of IFN-γ Studied in Experimental Autoimmune Encephalomyelitis Reveal Neutrophils As a Potential Target in Multiple Sclerosis.

The purinergic P2X7 receptor as a potential drug target to combat neuroinflammation in neurodegenerative diseases